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Background: Heat shock-related 70 kDa protein 2 (HSPA2) has been identified as a potential cancer-promoting
protein expressed at abnormal levels in a subset of cancers. However, its important role in esophageal squamous
cell carcinoma (ESCC) is hardly known by people. The purpose of this study is to assess HSPA2 expression and to
explore its role in ESCC.
Methods: Thirty ESCC samples, paired adjacent non-cancerous tissues and normal esophageal tissues, were
collected for HSPA2 detection by quantitative RT-PCR (qRT-PCR) and western blotting. Additionally, the expression
of HSPA2 in ESCC and adjacent non-cancerous tissues from 120 patients was analyzed by immunohistochemistry,
and correlated with clinicopathological parameters and patients’ outcome.
Results: HSPA2 mRNA and protein were overexpressed in ESCC tissues. Overexpression of HSPA2 was significantly
associated with primary tumor, TNM stage, lymph node metastases and recurrence, respectively (all, P <0.05).
Kaplan-Meier curves showed that elevated HSPA2 expression was associated with shorter disease-free survival and
overall survival in ESCC patients. Cox multivariate regression analysis revealed that overexpression of HSPA2 was an
independent prognostic factor in disease-free survival and overall survival for ESCC patients (hazard ratio was 2.115
and 2.210, respectively, P <0.05).
Conclusions: Our findings demonstrate that overexpression of HSPA2 may contribute to the malignant progression
of ESCC and present a novel prognostic indicator for ESCC patients.
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Esophageal cancer is the seventh leading cause of cancer
deaths worldwide, while its highest incidence and mortality
rates are found in Asia. For example, in China, the majority
of esophageal cancer diagnoses are esophageal squamous
cell carcinoma (ESCC), which is ranked as the eighth lead-
ing cause of death nationwide, mostly in northern China
where the incidence rate can be as high as 800 cases per
100,000 people [1]. The incidence and mortality rates of
ESCC have decreased over the last few decades in China.
On the contrary, it is continuing its march as the fastest
growing malignancy in the Western world [2]. ESCC* Correspondence: zcf6636169@sina.com
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reproduction in any medium, provided the orpatients have a high mortality rate and poor prognosis be-
cause of the high prevalence of invasion and metastasis.
Therefore, it is important to identify and characterize the
tumor-specific molecular markers involved in early stages
of ESCC that may contribute to ESCC carcinogenesis for
improving the survival of this disease.
Heat shock-related 70 kDa protein 2 (HSPA2, also
known as HSP70-2) is a member of the HSP70 family of
heat-shock proteins, mapped to 14q24.1 in one study [3]
and to 14q22 in another [4]. HSPA2 was originally found
specifically in primary spermatocytes and spermatids,
described as a testis-specific protein that played an im-
portant role in spermatogenesis [5,6]. Aberrant expres-
sion of HSPA2 in testes induced primary spermatocytes
to arrest in meiosis I and undergo apoptosis, which was
leading to male infertility [6]. Now HSPA2 has attractedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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carcinogenesis of non-testicular tissues. HSPA2 has
been identified as a potential cancer-promoting protein
expressed at abnormal levels in a subset of human can-
cers, such as breast cancer [7], cervical cancer [8], blad-
der urothelial cancer [9], nasopharyngeal carcinoma [10]
and malignant tumors [11]. Some level of the HSPA2
gene activity was also observed in cell lines derived from
several human cancers [12-14], while silencing of the
HSPA2 gene in cancer cells led to growth arrest and de-
crease in tumorigenic potential [8,9,12,15]. A HSPA2
mutation was recognized by cytotoxic T lymphocyte
(CTL) on a human renal cell carcinoma [16]. Further-
more, polymorphism in the HSPA2 gene is associated
with an increase in the risk of developing type 1 diabetes
[17], non-Hodgkin's lymphoma [18], lung cancer [19],
systemic lupus erythematosus (SLE) [20], rheumatoid
arthritis [21] and inflammatory bowel diseases [22].
Overexpression of HSPA2 is correlated with increased
cell proliferation, poor differentiation and lymph node
metastases in human breast cancer, cervical cancer and
bladder urothelial cancer [7-9]. The highest level of
HSPA2 was also detected in cells of the basal layers of
the skin, esophagus and bronchus epithelia. However,
whether there is HSPA2 expression in ESCC or not, has
not been reported in China and abroad so far.
Thus, in this study we used quantitative RT-PCR (qRT-
PCR), western blotting and immunohistochemistry to
evaluate HSPA2 expression and its correlation with the
survival of ESCC patients. Consistent with these studies,
we suggested that elevated HSPA2 expression was associ-
ated with poor survival of ESCC patients. Our findings
provide insights that could lead to better diagnosis, prog-
nosis and therapeutic opportunities for ESCC patients.Methods
Patients and tissue specimens
Primary ESCC samples, paired adjacent non-cancerous tis-
sues (from 2 to 3 cm away from the tumor margin) and
normal tissues (greater than 7 cm away from the tumor
margin) were obtained from 30 patients (20 males and 10
females, median age 52.73 years, range 35 to 69 years). The
patients underwent esophagus resection between January
2010 and June 2011 at Xiangya Hospital, Central South
University, Changsha, China. All patients were validated by
two pathologists. Before surgery, informed consent was
obtained from all patients, whose specimens were handled
and made anonymous according to the ethical and legal
standards. The study was approved by the Research Ethics
Committee of Central South University.
For immunohistochemical assays, 120 pairs of paraffin-
embedded ESCC samples, adjacent non-cancerous tissues
and normal tissues were obtained from patients whounderwent curative resection between January 2004 and
June 2007 at Xiangya Hospital. All patients had no history
of previous malignancies and no history of radiotherapy or
chemotherapy. Recurrence and metastasis were diagnosed
by imaging evaluation, clinical examination, operation and
postoperative pathological examination. In addition, the
patients involved in this study did not have any other dis-
eases which could cause infertility. The main clinical and
pathological variables of the patients are recorded in
Table 1. The follow-up time was 5 years for 120 patients,
ranging from 5 months to 60 months.
qRT-PCR
Total RNA was isolated by TRIzol extraction liquid
(Invitrogen, Carlsbad, CA, USA). Total RNA (2 μg) was re-
verse transcribed by cDNA Reverse Transcription Kits
(Invitrogen) according to the manufacturer’s instructions.
Primers were designed and synthesized by Sangon
Biological Engineering Technology and Services (Shanghai,
China). The primers for HSPA2 and β-actin were designed
as follows: HSPA2 primer (196 bp), forward 5’-AAAA
CAAAATCACCATCACCAAT-3’, reverse 5’-CTAATCTT
GCCCCTCAGTTTCTC-3’; β-actin primer (205 bp), for-
ward 5′-TGACGTGGACATCCGCAAAG-3′, reverse 5′-C
TGGAAGGTGGACAGCGAGG-3′. qRT-PCR was per-
formed with SYBR Green PCR Master Mix according to
the manufacturer’s instructions by using the CFX96 se-
quence detection system (Bio-Rad, Hercules, CA, USA)
and accompanying analytical software. The reaction
was first denatured at 95°C for 10 minutes, then 40 cycles
at 95°C for 10 seconds, 60°C for 20 seconds and followed
by 72°C for 10 seconds.Western blotting
HSPA2 protein was extracted using a Total Protein Ex-
traction Kit (Beyotime, Haimen, Jiangsu, China). Briefly,
all proteins were resolved on 10% SDS-PAGE in running
buffer and transferred to polyvinylidene difluoride mem-
branes (Millipore, Billerica, MA, USA). After blocking
with 5% milk for 2 hours, the membranes were incubated
with primary antibodies against HSPA2 (Santa Cruz
Biotechnology, Dallas, TX, USA) and glyceraldehyde 3-
phosphate dehydrogenase (GAPDH, Beyotime) at room
temperature for 2 hours. The membranes were then
washed with PBS Tween 20 and incubated with secondary
antibody goat anti-mouse immunoglobulin G (IgG)/horse-
radish peroxidase (HRP) (1:1000, Beyotime) for 1 hour at
room temperature. Enhanced chemiluminescence (ECL)
detection of the target protein was performed using a
Pierce ECL system (Thermo Scientific, Waltham, MA,
USA). HSPA2 protein expression levels were quantified by
Bio-Rad Image Lab software and presented as the densito-
metric ratio of the targeted protein to GAPDH.
Table 1 Correlation between HSPA2 expression and
clinicopathologic features of ESCC patients (n = 120)
Parameters Cases HSPA2 expression (n) χ2 P
valuePositive Negative
Tissues
Cancer 120 90 30 21.343 0.000
Adjacent 120 55 65
Age (years)
≤60 81 64 17 2.140 0.144
>60 39 26 13
Gender
Male 90 69 21 0.533 0.465
Female 30 21 9
Drinking
Yes 75 59 16 1.434 0.231
No 45 31 14
Tumor site
Upper 35 26 9 0.017 0.992
Middle 40 30 10
Lower 45 34 11
Grade
G1 63 49 14 0.672 0.715
G2 30 21 9
G3 + G4 27 20 7
Primary tumor
T1 30 18 12 9.340 0.025a
T2 31 21 10
T3 42 35 7
T4 17 16 1
TNM stage
I 28 14 14 14.991 0.001a
II 49 37 12
III 43 39 4
Lymph node metastases
N0 76 51 25 6.890 0.009a
N+ 44 39 5
Recurrenceb
Yes 85 70 15 8.497 0.004a
No 32 18 14
aP values considered statistically significant at <0.05; bthree patients lost to
follow-up because of telephone number changes or home moving. ESCC,
esophageal squamous cell carcinoma; G, grade; N, lymph node metastases;
T, primary tumor. Drinking alcohol is defined as average amount of drinking
alcohol is 50 grams or more per day, and period of drinking continues to 1 year
or more. Drinking alcohol parameter: amount of drinking/day × years of drinking.
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All specimens were fixed with 4% formaldehyde, dewaxed,
embedded and cut into 4 μm serial sections. Briefly,antigen retrieval was carried out in 10 mmol/l citrate buf-
fer (pH 6.0) for 15 minutes at 100°C in a microwave oven.
Endogenous peroxidase activity was blocked with 3%
hydrogen peroxide for 10 minutes at room temperature.
The sections were then incubated overnight at 4°C with
anti-HSPA2 antibody (Santa Cruz Biotechnology). After
washing with PBS, sections were incubated with secondary
antibodies for 30 minutes at 37°C. The sections were then
washed three times with PBS and treated with 3,3’-
diaminobenzedine (DAB) for approximately 5 minutes. Fi-
nally, the sections were counterstained with hematoxylin,
dehydrated, mounted and examined by light microscopy.
Negative controls were probed with PBS under the same
experimental conditions.
Immunohistochemical staining was assessed by two in-
dependent experienced pathologists who were blinded to
all clinicopathological features. Five high power fields in
each specimen were randomly selected, in which nuclear
and/or cytoplasmic staining was considered to be positive
staining for HSPA2. A staining index (values 0 to 9),
obtained as a product of staining intensity (0 to 3: 0 point,
no intensity; 1 point, weak intensity; 2 points, moderate
intensity; 3 points, strong intensity) multiplied by the pro-
portion of immunopositive cells of interest (≤10% = 1;
10% to 50% = 2; ≥50% = 3). Tumors were categorized into
three groups according to the final staining index: negative
or weak staining (scored 0 to 3), moderate staining (scored
4 to 6) and strong staining (scored 7 to 9). ESCC patients
were dichotomized into a negative expression group
(negative and weak staining scored 0 to 3), and positive
expression group (moderate and strong staining scored 4
to 9) in order to better analyze the prognosis between
groups.
Statistical analysis
All continuous variables were expressed as mean ± SD
from at least three separate experiments. HSPA2 levels
in ESCC samples, adjacent non-cancerous tissue and
normal tissues were examined by Wilcoxon signed-rank
test. The association between HSPA2 and clinicopatho-
logical features was analyzed using χ2 test. Survival
curves were obtained using Kaplan-Meier curves and
log-rank tests. Multivariate prognostic factors were ex-
amined by the Cox proportional hazards model. A value
of P <0.05 was considered to be statistically significant.
All statistical calculations were performed with SPSS
Statistics 18.0 software (IBM, Armonk, NY, USA).
Results
Expression of HSPA2 in different esophageal tissues
HSPA2 mRNA and protein expressions were detected in
the 30 pairs of primary ESCC samples, adjacent non-
cancerous tissues and normal tissues. The results in
Figure1A show that HSPA2 mRNA levels in the ESCC
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sues (3.1742 ± 1.6866 versus 1.2440 ± 0.6702, P <0.05).
However, no significant differences were found between ad-
jacent non-cancerous tissues and normal tissues (P >0.05).
We also found that HSPA2 mRNA had different expression
levels in the ESCC tissues at different tumor stages.
As shown in Figure 1B, HSPA2 mRNA expression in
advanced-stage ESCC tissues (n = 16) at stage III was sig-
nificantly higher than in early-stage ESCC tissues (n = 14)
at stages I and II (P <0.05). Western blotting analysis
showed that the HSPA2 protein expression in ESCC tissues
was significantly higher than in adjacent non-cancerous tis-
sues and normal tissues (P <0.05) (Figure 1C, D).
Correlation of HSPA2 expression with clinicopathological
characteristics of ESCC tissues
A total of 120 pairs of paraffin-embedded ESCC and ad-
jacent non-cancerous tissues were analyzed by immuno-
histochemistry. The positive expression rate of HSPA2
in ESCC tissues (90/120, 75%) was significantly higher
than in the adjacent non-cancerous tissues (55/120,
45.83%, P <0.05). As shown in Figure 2, HSPA2-positive
staining was predominantly observed in the nucleus and
some occurred in the cytoplasm. HSPA2 are classified asFigure 1 Comparison of HSPA2 mRNA and protein levels in ESCC sam
qRT-PCR and western blotting. (A) Relative HSPA2 mRNA expression leve
adjacent non-cancerous tissues; normal, normal esophageal tissues. (B) Rela
early and advanced. (C) Representative western blotting analysis of HSPA2
levels in different tissues. *P >0.05, compared with normal tissues; **P <0.05
The relative HSPA2 protein expression level in ESCC tissues is about 2.67 tim
adjacent non-cancerous tissues. Boxes represent the medians and interqua
squamous cell carcinoma; qRT-PCR, quantitative RT-PCR.cytosol/nuclear proteins able to translocate between the
cytoplasm and nucleus [14]. At physiological temperature,
the HSPA2 is localized primarily in cytoplasm, whereas
the HSPA2 localization shifts to the nucleus and nucleoli
in heat-hock cancer cells [14,23]. From immunohisto-
chemical analysis, the clinicopathological data of the pa-
tients are summarized in Table. 1. Overexpression of
HSPA2 was significantly associated with primary tumor,
TNM stage, lymph node metastases and recurrence re-
spectively (all, P <0.05). There were no significant differ-
ences in age, gender, drinking, tumor site or tumor grade.
Prognostic significance of HSPA2 expression in ESCC
patients
At the end of clinical follow-up, survival information was
available for 117 of 120 patients; three patients were lost to
follow-up because of telephone number changes or home
moving. Patients were divided into a HSPA2-positive group
(n = 90) and a HSPA2-negative group (n = 30). Kaplan-
Meier curves of survival analysis demonstrated that pa-
tients with HSPA2-positive expression had a shorter overall
survival than patients with HSPA2-negative expression
(survival rate: 18.9% versus 66.7%, P <0.001) (Figure 3).
Analysis of disease-free survival also obtained a similarples, adjacent non-cancerous tissues and normal tissues by
ls in different tissues: cancer, 30 paired ESCC samples; adjacent,
tive HSPA2 mRNA expression levels in ESCC tissues at different stages:
expression in all specimens. (D) Relative HSPA2 protein expression
, compared with normal tissues and adjacent non-cancerous tissues.
es of that in normal esophageal tissues, and 2.35 times of that in
rtile ranges of the normalized threshold values. ESCC, esophageal
Figure 2 Immunohistochemical analysis of HSPA2 in ESCC samples, adjacent non-cancerous tissues and normal esophageal tissues
(original magnification × 100). (A) Representative negative staining of HSPA2 in normal esophageal tissues. (B) Weak staining of HSPA2 in
adjacent non-cancerous tissues. (C) Representative moderate staining and (D) strong staining of HSPA2 in ESCC tissues. The expression of HSPA2
was detected in cells of the basal layers of the esophagus (B), and HSPA2-positive staining was predominantly observed in the nucleus and some
occurred in the cytoplasm in ESCC tissues (C,D). ESCC, esophageal squamous cell carcinoma.
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in Table 2, univariate analysis showed that overall survival
and disease-free survival were correlated with primary
tumor, TNM stage, lymph node metastases and HSPA2 ex-
pression. Furthermore, Cox multivariate regression analysis
indicated that HSPA2 expression, primary tumor and
TNM stage were considered as independent prognostic
factors for overall survival and disease-free survival in
Table 3.Figure 3 Overall survival and disease-free survival curves constructed
(negative expression, positive expression). (A) Overall survival and (B) d
B: χ2 = 18.149, P <0.001) demonstrated that ESCC patients in the HSPA2-po
disease-free survival compared with those in the HSPA2-negative expressio
number changes or home moving. ESCC, esophageal squamous cell carcinDiscussion
The HSPA2 gene was originally characterized as a coun-
terpart of the testis-specific rodent HST70/HSP70-2 gene,
which was specially and highly expressed in the testis
[5,6]. Recently, research has shown that human tumor
cells and some somatic tissues can express this gene at sig-
nificant levels [7-10,12-14]. The polymorphism of HSPA2
at position 1267 has been suggested to be associated with
carcinogenesis in many malignant cancer tissues [7-10].by Kaplan-Meier analysis, grouped by HSPA2 expression
isease-free survival curves. Log-rank test (A: χ2 = 16.180, P <0.001;
sitive expression group had shorter overall survival and poorer
n group. Three patients were lost to follow-up because of telephone
oma.
Table 2 Univariate survival analysis of overall survival and disease-free survival in 120 patients with ESCC
Features Overall survival Disease-free survival
Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
Age (≤60/>60 years) 0.713 (0.456 to 1.116) 0.139 0.745 (0.493 to 1.125) 0.162
Gender (female/male) 0.915 (0.553 to 1.513) 0.728 0.975 (0.624 to 1.525) 0.913
Drinking (yes/no) 1.043 (0.670 to 1.622) 0.853 1.017 (0.681 to 1.518) 0.935
Tumor site (upper + lower/middle) 1.347 (0.797 to 2.277) 0.266 1.216 (0.768 to 1.926) 0.405
Grade (G2 + G3 + G4/G1) 1.137 (0.739 to 1.749) 0.559 1.070 (0.723 to 1.584) 0.735
Primary tumor (T3 + T4/T1 + T2) 2.157 (1.380 to 3.372) 0.001a 1.872 (1.256 to 2.791) 0.002a
TNM stage (III/I + II) 21.177 (11.057 to 40.561) <0.001a 15.085 (8.320 to 27.350) <0.001a
Lymph node metastases (−/+) 0.572 (0.369 to 0.887) 0.012a 0.625 (0.418 to 0.935) 0.022a
HSPA2 expression (positive/negative) 3.557 (1.827 to 6.922) <0.001a 2.901 (1.721 to 4.888) <0.001a
aP values considered statistically significant at <0.05. CI, confidence interval; ESCC, esophageal squamous cell carcinoma; G, grade; N, lymph node metastases;
T, primary tumor. Drinking alcohol is defined as: average amount of drinking alcohol is 50 grams or more per day, and period of drinking continues to 1 year or
more. Drinking alcohol parameter: amount of drinking/ day × years of drinking.
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basal layers of the esophagus [23], but the function of
HSPA2 in basal cells, which may be involved in the prolif-
eration and/or differentiation of epidermal keratinocytes,
is currently unknown.
In this study, the expression levels of HSPA2 mRNA
and protein in the ESCC tissues were significantly higher
than in adjacent non-cancerous tissues and normal
esophageal tissues, consistent with other cancer reports
[7-9]. As a chaperone protein, HSPA2 is essential for the
growth of spermatocytes and cancer cells, and it is
known to be involved in apoptosis and regulation of cell
proliferation [18]. Silencing the expression of the HSPA2
gene by RNA interference suggests that HSPA2 increases
the growth rate and tumorigenic potential not only in
the cell culture but also in tumor xenograft in mice
[7-9,15]. However, the underlying mechanisms for the
high expression of HSPA2 in tumors remain incom-
pletely understood, but likely involve regulatory pro-
cesses, such as cell cycling. Indeed, HSPA2 appears to be
a molecular chaperone for CDC2 and is required for
CDC2/cyclinB1 complex formation, whose destruction
can prevent development of the CDC2 kinase activity,
required to trigger G2/M phase transition [24]. During
meiosis, spermatogenic cells synthesize HSPA2, knock-
out of HSPA2 in HSPA2 (−/−) male mice testes induceTable 3 Multivariate survival analysis of overall survival and d
Features Overall survi
Hazard ratio (95% CI)
Primary tumor (T3 + T4/T1 + T2) 1.746 (1.104 to 2.762)
TNM stage (III/I + II) 16.347 (8.560 to 31.215)
Lymph node metastases (−/+) 0.838 (0.534 to 1.315)
HSPA2 expression (positive/negative) 2.210 (1.101 to 4.435)
aP values considered statistically significant at <0.05. CI, confidence interval; ESCC, e
T, primary tumor.primary spermatocytes to arrest in meiosis I and undergo
a dramatic increase in spermatocyte apoptosis, which was
leading to male infertility [6]. HSPA2 overexpression
protects V79 fibroblasts against bortezomib-induced apop-
tosis [25]. The mechanism of a mutated HSPA2 chaperone
has a dominant effect in tumor cells by triggering the G2/
M phase transition during the mitotic cell cycle, which
could explain the HSPA2 abnormal expression in somatic
tumors. Moreover, downregulation of lens epithelium-
derived growth factor (LEDGF) is responsible for the
death of HSPA2-depleted cancer cells and LEDGF pos-
sesses great oncogenic potential [26]. HSPA2 may also
have a potential role in cancer pathogenesis by participat-
ing in the regulation of antitumor immunity, such as act-
ing as a chaperone molecule for immunogenic tumor-
associated peptides [27], while HSPA2 has been identified
as a putative susceptibility locus in organ-specific auto-
immune diseases. Lastly, a new regulatory mechanism of
HSPA2 expression in tumor cells has been disclosed,
which suggests that the upregulation of HSPA2 enhanced
the resistance of tumor cells to hypoxia-induced apoptosis,
which provides a new insight into how tumor cells over-
come hypoxic stress and survive [28].
Immunohistochemical analysis of a large set of speci-
mens revealed that HSPA2 protein was positively
expressed in 75% (90/120) ESCC tissues, compared toisease-free survival in 120 patients with ESCC
val Disease-free survival
P value Hazard ratio (95% CI) P value
0.017a 1.516 (1.005 to 2.289) 0.048a
<0.001a 11.729 (6.448 to 21.335) <0.001a
0.442 0.906 (0.596 to 1.375) 0.642
0.026a 2.115 (1.222 to 3.661) 0.007a
sophageal squamous cell carcinoma; G, grade; N, lymph node metastases;
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(P <0.05). We correlated HSPA2 protein expression
with various clinicopathological factors in 120 ESCC pa-
tients. Our results showed that overexpression of
HSPA2 was significantly associated with primary tumor,
TNM stage, lymph node metastases and recurrence re-
spectively (all, P <0.05). We also found HSPA2 mRNA
expression in advanced-stage ESCC tissues at stage III
was significantly higher than in early-stage ESCC tissues
at stages I and II. These data revealed a potential associ-
ation between HSPA2 overexpression and malignant
phenotypes, such as metastasis, consistent with other
reports in breast cancer [7], cervical cancer [8] and
bladder urothelial carcinoma [9]. It is well known that
the HSPA2 is localized primarily in cytoplasm at physio-
logical temperature, whereas HSPA2 migrates to the nu-
cleus and nucleoli under heat-shock conditions [14,23],
and our results confirm this theory. The phenomenon
of HSPA2 translocation into the nucleus and nucleoli
has been presently found in many other heat-shock can-
cer cells, which is part of a cellular protective response
under stress conditions, but the mechanism is currently
unknown. Generally, HSPA2 is involved in intracellular
trafficking and nuclear receptor binding, which also
prevents inappropriate protein aggregation and medi-
ates transport of immature (or damaged) proteins to
target subcellular compartments for final packaging,
degradation or repair [29]. Since HSPA2 shuttles con-
tinuously between the cytoplasm and nucleus during
heat-shock, this cell migration is critical for tumor for-
mation and metastasis.
It is widely accepted that metastasis contributes to the
high mortality rate for patients with ESCC. Our data re-
vealed that high HSPA2 protein expression was well cor-
related with lymph node metastasis and predicted worse
prognosis. Although close association between HSPA2
expression and ESCC metastasis has been established in
our study, the possible mechanisms are still unclear and
need further investigation. Moreover, lymph node metas-
tasis is one of the vital elements of TNM stage. It is also
well known that lymph node metastasis frequently oc-
curs in advanced-stage ESCC patients. Therefore, it is
not difficult to explain the reason for overexpression of
the HSPA2 gene in late stages. The abnormal excessive
proliferation of tumor cells also frequently occurs in late
stages and overexpression of HSPA2 can promote devel-
opment of the CDC2 kinase activity, required to trigger
G2/M phase transition and regulate cell proliferation
through controlling cell cycling. The overexpression of
HSPA2 leads to the prolonged cell cycling arrest at the
G2 phase. Most importantly, the resistance of tumor
cells to hypoxia-induced apoptosis in late stages is very
strong and the new regulatory mechanism mentioned
above indicates that the upregulation of HSPA2 mayenhance the resistance of tumor cells to hypoxia-induced
apoptosis. All these theories illustrate that overexpression
of HSPA2 promotes the occurrence and development of
ESCC.
Finally, patients with HSPA2-positive expression were
significantly associated with shorter disease-free and
overall survival by using the Kaplan-Meier analysis.
Therefore, HSPA2 protein expression pattern might be a
valuable prognostic marker for ESCC patients. More im-
portantly, from univariate and multivariate analysis, we
obtained sufficient evidence to deduce that HSPA2 ex-
pression level was an independent prognostic indicator
for patients with ESCC. Overexpression of HSPA2 is
correlated with poor therapeutic outcomes in human
breast cancer, cervical cancer and bladder urothelial can-
cer; furthermore, it is now a valuable prognostic marker
for breast cancer patients [7]. The polymorphism of
HSPA2 acts as an attractive susceptibility marker and in-
dependent prognostic indicator in Kangri cancer patients
[30]. Considering the frequency of positivity of HSPA2
in adjacent non-cancerous tissues is much higher,
whether or not HSPA2 molecule can be qualified to be a
prognostic biomarker will need to be validated in future
clinical work.
Conclusions
Our present study demonstrated that elevated HSPA2 ex-
pression levels was positively associated with the progres-
sion and poor prognosis in patients with ESCC, which
indicated that HSPA2 might serve as a valuable prognosis
marker for ESCC patients. However, the possible under-
lying mechanisms for its participation in ESCC progres-
sion are still unclear. Therefore, the next step we will take
will be further research of the cell signaling pathway in
order to gain a better molecular mechanism understand-
ing in this field.Abbreviations
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